ERBB2 and gastric carcinoma: Moreover, the introduction of a novel type of treatment, called antibody–drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), has expanded the range of therapeutic options for HER2-low breast and gastric carcinomas [5].